2015
DOI: 10.1016/j.jcv.2015.01.015
|View full text |Cite
|
Sign up to set email alerts
|

Viral load in children with congenital cytomegalovirus infection identified on newborn hearing screening

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

2
14
1
6

Year Published

2018
2018
2024
2024

Publication Types

Select...
9

Relationship

2
7

Authors

Journals

citations
Cited by 35 publications
(23 citation statements)
references
References 23 publications
2
14
1
6
Order By: Relevance
“…All of these studies screened infants who failed their initial newborn hearing screen. One prospective cohort study21 identified six infants with cCMV and SNHL. All infants were treated with valganciclovir for 6 weeks, with only one child experiencing an improvement in hearing at 1 year of age.…”
Section: Discussionmentioning
confidence: 99%
“…All of these studies screened infants who failed their initial newborn hearing screen. One prospective cohort study21 identified six infants with cCMV and SNHL. All infants were treated with valganciclovir for 6 weeks, with only one child experiencing an improvement in hearing at 1 year of age.…”
Section: Discussionmentioning
confidence: 99%
“…CMV genome load in urine decreased to 614 copies/mL at the end of 6 weeks of treatment and did not increase after treatment was completed. The increase of viral loads in blood was observed after completion of ganciclovir therapy, but we did not treat this because the rebound increase of the CMV genome load was reported in earlier report and exacerbation of clinical findings was not observed (16). We assume that the decline in CMV viral load in blood and urine reflects a favorable response to treatment.…”
mentioning
confidence: 86%
“…It would also enable an earlier identification and correction of the main cause of hearing loss with post-natal onset [5]. If, for any reason, a neonatal cCMV screening is not feasible on a large scale, at least a hearing-targeted cCMV screening should be set up: it would allow the early identification of children with cCMV-related hearing loss, although it would miss delayed hearing losses or other cCMV-related disease [3, 4, 9]. The following benefits from hearing-targeted CMV screening can be underlined; i) it would provide an accurate assessment of the aetiology of childhood deafness, helping physicians in children’s management and follow-up; ii) it would allow an adequate counselling and support to parents; iii) it would help predicting whether another child might be born with hearing-linked damages and, finally, iv) it could alert clinicians on the possible neurological and behavioural complications.…”
Section: Discussionmentioning
confidence: 99%
“…A wide range of diseases, diagnosed either at birth or in childhood, has been correlated to cCMV infection [1]; sensorineural hearing loss is the most frequent permanent damage, occurring in 5–40% of infected children, either symptomatic or not at birth; as a matter of fact, cCMV is the most common cause of non-genetic deafness in childhood [2]. An early identification of infected children – ideally through a universal neonatal screening - might allow a prompt treatment, aimed at limiting the hearing loss progression and possibly preventing the onset of cCMV-linked damages to the central nervous system in both symptomatic and asymptomatic babies [3, 4]. …”
Section: Introductionmentioning
confidence: 99%